Condition: Hepato Cellular Carcinoma (HCC) · Portal Vein Tumour Thrombosis · Sponsor: Tanta University
The goal of this cross-sectional observational study is to evaluate the relation between Prothrombin induced by vitamin K absence II (PIVKA-II) and the presence of portal vein tumor thrombosis (PVTT) in hepatocellular carcinoma (HCC) patients. Researchers will compare PIVKA-II serum levels in HCC patients with PVTT and without PVTT. Participants will undergo history-taking, clinical examination, laboratory investigations, PIVKA-II serum level, Child-Pugh classification, Model for End-stage Liver Disease (MELD) score, BCLC staging, abdominal ultrasonography, and Triphasic CT abdomen with contrast or MRI to evaluate tumor site, size, number, and presence of PVTT (a filling defect in the portal vein or its branch to distinguish PVTT or thrombus).
This description comes directly from the study's public registry record.
Rania M Elkafoury, MD · +201004672358 · rania.elkafoury@med.tanta.edu.eg
Nabila A Elgazzar, MD · 00201288585733 · nabilaelgazzar@med.tanta.edu.eg
Always discuss trial participation with your own doctor first.
| Tanta University Hospitals | Tanta, Gharbyea, Egypt | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06960954